mangalore today
name
name
name
Saturday, February 01
namenamename

 

Bharat Biotech’s nasal Covid booster gets nod for trial in India


Mangalore Today News Network

New Delhi, Jan 28, 2022: The Drugs Controller General of India (DCGI) has given its approval to Bharat Biotech for trials of its intranasal Covid booster dose in India. The trials will be done on 900 subjects.

 

Nasal Covid booster


DCGI’s Subject Expert Committee (SEC) gave an ‘in-principle’ approval to Bharat Biotech for the ’phase-III booster dose study’ for its intranasal Covid vaccine, a first of its kind in India, and asked it to submit protocols for approval 3 weeks ago.

Bharat Biotech is the second company to submit an application for the phase-III trial of the third dose in India. The intranasal vaccines reportedly have the potential to prevent transmission for new Covid-19 variants such as Omicron.

India has approved Covidshield, Covaxin and Sputnik V for vaccination in the country. Covaxin is approved for use under the 28-day Multi-Dose Vial Policy (MDVP) from DCGI and the WHO Emergency Use Listing (WHO EUL).


Courtesy:India Today


Write Comment | E-Mail To a Friend | Facebook | Twitter | Print
Error:NULL
Write your Comments on this Article
Your Name
Native Place / Place of Residence
Your E-mail
Your Comment
You have characters left.
Security Validation
Enter the characters in the image above